Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Mechanism of c-MET in Non-small Cell Lung Cancer and Its Treatment and Testing].

Zhongguo fei ai za zhi = Chinese journal of lung cancer - 1 Dec 2015

Liang Hongge, Wang Mengzhao

Abstract excerpt

Hepatocyte growth factor/c-MET (HGF/c-MET) signaling pathway can be abnormal activated by many mechanisms such as c-MET mutation, amplification and the overexpression of HGF, and it plays an important role in the development of non-small cell lung cancer (NSCLC), as well as in the tolerance of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in NSCLC. Therefore, c-MET is a new molecular...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Enzyme Inhibitors
Share to ALK gene

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to HGF gene

Share to MET gene

Share to Lung Neoplasms

Share to Mutation

Share to Proto-Oncogene Proteins c-met

Source

Open in PubMed Open full text

Identifiers

PMID: 26706951
DOI: 10.3779/j.issn.1009-3419.2015.12.06
PMCID: PMC6015186

Genes

MET
EGFR
HGF
ALK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Mechanism of c-MET in Non-small Cell Lung Cancer and Its Treatment and Testing].PMID 26706951Read ↗

[Research Progresses in the Treatment of NSCLC with MET Gene Variants: A Riview].Semantic proximity Read ↗

[Progress on Mechanism of MET Gene Mutation and Targeted Drugs in Non-small Cell Lung Cancer].Semantic proximity Read ↗

[Drug Resistance Mechanism and Therapeutic Strategy of Targeted Therapy of Non-small Cell Lung Cancer with MET Alterations].Semantic proximity Read ↗

The METeoric rise of MET in lung cancerSemantic proximity Read ↗

[Status quo of research on HGFc-Met signaling pathway in cancers].Semantic proximity Read ↗

[Clinicopathological Features and Prognosis of Patients Newly Diagnosed With Lung Adenocarcinoma With Both EGFR Mutation and C-MET Amplification].Semantic proximity Read ↗

MET as a possible target for non-small-cell lung cancer.Semantic proximity Read ↗

Targeting mesenchymal-epithelial transition factor signaling in cancer: from genetic alterations to clinical advances and future prospects.Semantic proximity Read ↗

Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunitiesSemantic proximity Read ↗

MET: a new promising biomarker in non-small-cell lung carcinoma.Semantic proximity Read ↗

MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies.Semantic proximity Read ↗

Met inhibitors in the treatment of lung cancer: the evidence to date.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.